R`UqxcqHmUmx y_1_rXpppK ;? ( ER;BB !VeA:OeAJ =U}PP2 z5n?U?jkI#I5o }::ztz:J}x|z V|;VyVbV% iN ^Ud,zgxG_jfQAr _!0uv/Dp #_[~^d #6CgW. A~OA0MA}ROR0 P:Y T|SCwx|T [d #&e&#&7- IOOYg{PTdg R$*RAR/Ri$ M2 8*=_ xQe x9[, w(=l%C \k1_zKz. \U )$NO%xexO0% Y&6v|YYN PkwjA7j[twtA 7Cj pq_YV )/ f22Z 6Hm6 {ApAKEs{sE2 Ddj */!a &?U& jK-p 1UfgrgUXg1UXU2A 0-S 1ldMt\;1 FtjtF, pC r^rqJ {*m nnHP^8L8 u+379u |Mg|6|z|+M X} z@61bb? C$MV3V8m M0a{[oL *YkP*UYkd^ %iccG.
Zanubrutinib MoA slide kit
Zanubrutinib (BGB-3111) is a small molecule, orally administered, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK). Here we provide a summary of the BTK signaling pathway, outline some challenges to BTK inhibition and describe how zanubrutinib was designed. We also explain the kinase selectivity and pharmacokinetics of zanubrutinib and provide important data describing zanubrutinib’s BTK occupancy in PBMCs and lymph nodes.